Bharat Biotech has unveiled Nucelion, a wholly-owned subsidiary positioned as a Contract Research, Development & Manufacturing Organisation (CRDMO) specialising in advanced cell and gene therapies. The new entity, based in Genome Valley, Hyderabad, is designed to partner with global life-science innovators to deliver end-to-end solutions for complex biologic medicines.

Nucelion will develop infrastructure for plasmid production, viral and non-viral vectors, autologous and allogeneic cell therapies, and aseptic fill-and-finish services, supporting project progression from preclinical stages to commercial production. Leadership and operations will be independent, operating on arm’s-length commercial terms with Bharat Biotech.

This move reinforces Bharat Biotech’s strategic expansion beyond vaccines into next-generation biologics, with the aim of advancing India’s role as a hub for biomanufacturing and increasing access to cutting-edge treatments.